Intracameral bevacizumab for iris rubeosis

被引:151
作者
Grisanti, Salvatore [1 ]
Biester, Sabine [1 ]
Peters, Swaantje [1 ]
Tatar, Olcay [1 ]
Ziemssen, Focke [1 ]
Bartz-Schmidt, Karl Ulrich [1 ]
机构
[1] Univ Tubingen, Dept Ophthalmol 1, D-72076 Tubingen, Germany
关键词
D O I
10.1016/j.ajo.2006.02.045
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
PURPOSE: To determine whether intracameral bevacizumab decreases vascular leakage from iris rubeosis in patients with neovascular glaucoma. DESIGN: Interventional case series. METHODS: The study included six eyes of three patients with secondary neovascular glaucoma due to proliferative diabetic retinopathy (n = 2) or ischemic central retinal vein occlusion (n = 1). All patients received an intracameral injection of 1.0 mg bevacizumab. Morphologic changes and vascular leakage were investigated prospectively by iris fluorescein angiography. RESULTS: Decrease in leakage was detected as early as one day after injection. No inflammation was observed. No relapse was seen within the follow-up of four weeks. CONCLUSION: Intraocular injection of bevacizumab may provide an additional strategy for the treatment of iris rubeosis in neovascular glaucoma.
引用
收藏
页码:158 / 160
页数:3
相关论文
共 4 条
[1]  
EHRENBERG M, 1984, OPHTHALMOLOGY, V91, P321
[2]   Vascular endothelial growth factor: Basic science and clinical progress [J].
Ferrara, N .
ENDOCRINE REVIEWS, 2004, 25 (04) :581-611
[3]   Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer [J].
Hurwitz, H ;
Fehrenbacher, L ;
Novotny, W ;
Cartwright, T ;
Hainsworth, J ;
Heim, W ;
Berlin, J ;
Baron, A ;
Griffing, S ;
Holmgren, E ;
Ferrara, N ;
Fyfe, G ;
Rogers, B ;
Ross, R ;
Kabbinavar, F .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (23) :2335-2342
[4]   Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin®) for neovascular age-related macular degeneration [J].
Rosenfeld, PJ ;
Moshfeghi, AA ;
Puliafito, CA .
OPHTHALMIC SURGERY LASERS & IMAGING, 2005, 36 (04) :331-335